The para substitution of the centralaromatic ring perfectly fits the narrow MAOB’s active site.As typically observed in MAOB structure-bound bulky elongated inhibitors,the gating Ile199 is in an open conformation, allowing binding ofthe terminal benzoxazole moiety.52 Indeed,superposition with the structure in complex with rasagiline, a clinicallyused propargylamine-based anti-Parkinson’s disease drug, showsan identical active-site conformation, except for some differencesat the entrance cavity (Phe103, His115, and Trp119; Figure 5B,C). This evidence concerns the gene MAOB and Parkinson disease.